Shares of the company are trading at $1.52 barely above the 50 day moving average of $1.43 and which is a tad above the 200 day moving average of $1.45. The 50 day moving average was up $0.09 and the 200 day average went up by +5.10%. Trading volume for OvaScience Inc. was 120K on Tuesday. Overall, volume was down 54.97% under the stocks normal daily volume.
Investors are feeling more bullish on OvaScience Inc. of late at least if you consider the fall in short interest. The stock saw a fall in short interest between September 29, 2017 and October 13, 2017 of -5.57%. Short interest decreased from 3,207,923 to 3,029,199 over that timeframe. With short interest at 3,029,199 and short average daily volume at 339,628, the short-interest ratio is 9.0 and the short interest percentage is 0.08% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (OVAS). As of quarter end Sabby Management, LLC had bought 85,525 shares growing its stake by 20.2%. The value of the investment in (OVAS) increased from $792,000 to $795,000 increasing 0.4% for the reporting period. As of the end of the quarter Ubs Group Ag had disposed of a total of 2,399 shares trimming its position 90.1%. The value of the total investment in OvaScience Inc. went from $5,000 to $0 a change of $5,000 since the last quarter.
As of the end of the quarter Meeder Asset Management Inc had acquired 4,085 shares growing its holdings by 583.6%. The value of the investment in OVAS increased from $1,000 to $7,000 a change of 600.0% quarter over quarter. Northern Capital Management LLC cut its ownership by selling 800 shares a decrease of 0.9% in the quarter. Northern Capital Management LLC claims 91,065 shares with a value of $129,000. The value of the position overall is down by 9.8%.
As of the latest earnings report the EPS was $-2.11 and is projected to be $-1.70 for the current year with 35,686,000 shares now outstanding. Analysts expect next quarter’s EPS will be $-0.38 and the next full year EPS is projected to be $-1.24.
OvaScience, Inc., launched on April 5, 2011, is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Business’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Business’s AUGMENT treatment is specifically designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization (IVF) process to supplement the existing mitochondria..